v3.26.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
Schedule of Segment Reporting

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment. A reconciliation to the consolidated net loss for the three months ended March 31, 2026 and 2025 is included at the bottom of the table below (in thousands):

 

 

For the Three Months
Ended March 31,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

Tegoprubart - kidney transplantation programs

 

$

5,414

 

 

$

8,531

 

Tegoprubart - other development programs

 

 

—

 

 

 

(168

)

Manufacturing

 

 

7,786

 

 

 

1,670

 

Personnel-related expenses

 

 

3,803

 

 

 

3,448

 

Stock-based compensation

 

 

2,202

 

 

 

2,864

 

Other segment items*

 

 

1,976

 

 

 

1,619

 

Total operating expenses

 

 

21,181

 

 

 

17,964

 

Loss from operations

 

 

(21,181

)

 

 

(17,964

)

Other income, net

 

 

1,118

 

 

 

1,409

 

Change in fair value of warrant liabilities

 

 

(18,962

)

 

 

10,060

 

Net loss

 

$

(39,025

)

 

$

(6,495

)

* Other segment items included in total operating expenses primarily consist of consulting, professional fees, facilities, insurance and information technology.